Literature DB >> 1749214

Inborn errors of bile acid metabolism.

P T Clayton1.   

Abstract

Cholesterol is converted to cholic acid and chenodeoxycholic acid by a series of reactions involving modifications to the steroid nucleus and oxidation of the side chain. These reactions can be affected by a number of inborn errors of metabolism. When this happens unusual bile acids or bile alcohols are synthesized; these can be identified using gas chromatography-mass spectrometry and fast atom bombardment mass spectrometry techniques. Two defects affecting the modifications to the steroid nucleus have been described; both present with cholestatic liver disease of neonatal onset. The better characterized of the two--3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency--leads to excretion of 3 beta-7 alpha-dihydroxy-5-cholenoic acid and 3 beta,7 alpha,12 alpha-trihydroxy-5-cholenoic acid in the urine. The liver disease improves dramatically on treatment with chenodeoxycholic acid. Deficient activity of 3-oxo-delta 4-steroid 5 beta-reductase is thought to be the cause of familial liver disease in some infants who excrete 7 alpha-hydroxy-3-oxo-4-cholenoic acid and 7 alpha,12 alpha-dihydroxy-3-oxo-4-cholenoic acid in the urine. However, diagnosis of this disorder is problematical; a similar pattern of metabolite excretion can occur as a result of liver damage caused by viruses or inborn errors of pathways unrelated to bile acid synthesis. Defective side chain oxidation in patients with cerebrotendinous xanthomatosis (CTX) leads to synthesis of bile alcohols such as 5 beta-cholestane-3 alpha,7 alpha,12 alpha,25-tetrol and 5 beta-cholestane-3 alpha,7 alpha,12 alpha,23,25-pentol. Patients with CTX do not have cholestatic liver disease. Their major problems (neurological disease, atherosclerosis and xanthomata) are caused by accumulation of cholestanol and cholesterol in the tissues. Bile acid precursors are probably diverted into synthesis of cholestanol. Chenodeoxycholic acid suppresses the production of abnormal metabolites from cholesterol (by inhibition of cholesterol 7 alpha-hydroxylase) and leads to improvement in the neurological disease. Defective side chain oxidation also occurs in peroxisomal disorders but this time it leads to accumulation of C27 bile acids such as 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholestanoic acid (trihydroxycoprostanic acid, THCA). This compound is readily detected in the bile and plasma of patients with defects of peroxisome biogenesis. In patients with defects of a single peroxisomal beta-oxidation enzyme (the 3-hydroxyacyl-CoA component of the bifunctional protein or the thiolase), the major C27 bile acid in bile may be 3 alpha,7 alpha,12 alpha,24-tetrahydroxy-5 beta-cholestanoic acid (varanic acid).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1749214     DOI: 10.1007/bf01797919

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  56 in total

1.  A new peroxisomal disorder: di- and trihydroxycholestanaemia due to a presumed trihydroxycholestanoyl-CoA oxidase deficiency.

Authors:  E Christensen; J Van Eldere; N J Brandt; R B Schutgens; R J Wanders; H J Eyssen
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

2.  Occurrence of bile alcohols in the bile of a patient with cholestasis.

Authors:  A Kibe; S Nakai; T Kuramoto; T Hoshita
Journal:  J Lipid Res       Date:  1980-07       Impact factor: 5.922

3.  Regulation of bile acid synthesis. I. Effects of conjugated ursodeoxycholate and cholate on bile acid synthesis in chronic bile fistula rat.

Authors:  D M Heuman; C R Hernandez; P B Hylemon; W M Kubaska; C Hartman; Z R Vlahcevic
Journal:  Hepatology       Date:  1988 Mar-Apr       Impact factor: 17.425

4.  Detection of carriers of cerebrotendinous xanthomatosis.

Authors:  B J Koopman; R J Waterreus; H W Van den Brekel; B G Wolthers
Journal:  Clin Chim Acta       Date:  1986-07-30       Impact factor: 3.786

5.  Peroxisomal bifunctional enzyme deficiency.

Authors:  P A Watkins; W W Chen; C J Harris; G Hoefler; S Hoefler; D C Blake; A Balfe; R I Kelley; A B Moser; M E Beard
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

6.  C27 bile acids in infants with coprostanic acidemia and occurrence of a 3 alpha,7 alpha,12 alpha-tridhydroxy-5 beta-C29 dicarboxylic bile acid as a major component in their serum.

Authors:  G G Parmentier; G A Janssen; E A Eggermont; H J Eyssen
Journal:  Eur J Biochem       Date:  1979-12

7.  Serum bile acid profiles in cerebrotendinous xanthomatosis.

Authors:  T Beppu; Y Seyama; T Kasama; S Serizawa; T Yamakawa
Journal:  Clin Chim Acta       Date:  1982-02-05       Impact factor: 3.786

8.  Capillary gas chromatographic determinations of urinary bile acids and bile alcohols in CTX patients proving the ineffectivity of ursodeoxycholic acid treatment.

Authors:  B J Koopman; B G Wolthers; J C van der Molen; G T Nagel; R J Waterreus; H J Oosterhuis
Journal:  Clin Chim Acta       Date:  1984-09-15       Impact factor: 3.786

9.  Effect of chenodeoxycholic acid on biliary and urinary bile acids and bile alcohols in cerebrotendinous xanthomatosis; monitoring by high performance liquid chromatography.

Authors:  A K Batta; S Shefer; M Batta; G Salen
Journal:  J Lipid Res       Date:  1985-06       Impact factor: 5.922

10.  Subcellular distribution and characteristics of trihydroxycoprostanoyl-CoA synthetase in rat liver.

Authors:  L Schepers; M Casteels; K Verheyden; G Parmentier; S Asselberghs; H J Eyssen; G P Mannaerts
Journal:  Biochem J       Date:  1989-01-01       Impact factor: 3.857

View more
  10 in total

Review 1.  Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines.

Authors:  Nancy E Braverman; Gerald V Raymond; William B Rizzo; Ann B Moser; Mark E Wilkinson; Edwin M Stone; Steven J Steinberg; Michael F Wangler; Eric T Rush; Joseph G Hacia; Mousumi Bose
Journal:  Mol Genet Metab       Date:  2015-12-23       Impact factor: 4.797

2.  Niemann-Pick disease type C and defective peroxisomal beta-oxidation of branched-chain substrates.

Authors:  J S Sequeira; A Vellodi; M T Vanier; P T Clayton
Journal:  J Inherit Metab Dis       Date:  1998-04       Impact factor: 4.982

3.  Characterization of disease-related 5beta-reductase (AKR1D1) mutations reveals their potential to cause bile acid deficiency.

Authors:  Jason E Drury; Rebekka Mindnich; Trevor M Penning
Journal:  J Biol Chem       Date:  2010-06-03       Impact factor: 5.157

4.  An inborn error of bile acid synthesis (3beta-hydroxy-delta5-C27-steroid dehydrogenase deficiency) presenting as malabsorption leading to rickets.

Authors:  A K Akobeng; P T Clayton; V Miller; M Super; A G Thomas
Journal:  Arch Dis Child       Date:  1999-05       Impact factor: 3.791

5.  No linkage to the 3 beta-HSD gene cluster in a kindred affected with 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency and early onset hepatic failure.

Authors:  A Russell; H Nazer; A Shams; J Sjövall; R Sutcliffe
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

Review 6.  Biochemistry of peroxisomes in health and disease.

Authors:  I Singh
Journal:  Mol Cell Biochem       Date:  1997-02       Impact factor: 3.396

Review 7.  Optic atrophies in metabolic disorders.

Authors:  Marjan Huizing; Brian P Brooks; Yair Anikster
Journal:  Mol Genet Metab       Date:  2005-09-27       Impact factor: 4.797

8.  Diagnosis of the first Japanese patient with 3-oxo-delta4-steroid 5beta-reductase deficiency by use of immunoblot analysis.

Authors:  A Kimura; K H Kondo; K I Okuda; S Higashi; M Suzuki; T Kurosawa; M Tohma; T Inoue; A Nishiyori; M Yoshino; H Kato; T Setoguchi
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

Review 9.  Bile acids: the role of peroxisomes.

Authors:  Sacha Ferdinandusse; Simone Denis; Phyllis L Faust; Ronald J A Wanders
Journal:  J Lipid Res       Date:  2009-04-08       Impact factor: 5.922

Review 10.  Investigation of paediatric liver disease.

Authors:  D Kelly; A Green
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.